

## Review Form 1.6

Journal Name:	<a href="#">Journal of Pharmaceutical Research International</a>
Manuscript Number:	Ms_JPRI_79539
Title of the Manuscript:	Cardiotoxicity among patients using Pertuzumab, Trastuzumab, and Taxane with HER2-Positive Early-Stage Breast Cancer: A Single Centre Experience
Type of the Article	Original Research Article

### **General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

<https://www.journaljpri.com/index.php/JPRI/editorial-policy>

**Review Form 1.6**

**PART 1: Review Comments**

	<b>Reviewer's comment</b>	<b>Author's comment</b> (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Compulsory</b> REVISION comments	<p><b>Page 4:</b> „Specifically, a 1% decline from the basal reading of ejection fraction (EF) was considered as the presence of cardiotoxicity incidence”                      For LVEF measuring using echocardiography, there is an error above 1%, depending on multiple factors, so I believe that the cutoff value should be above 1%, adapted to the mean variation of the echocardiography laboratory that performed the tests.</p> <p><b>Page 6:</b> „In multivariate analysis, there were statistically significant associations between pertuzumab (OR 3.52, 95% CI (1.5-8.22)) and its combinations pertuzumab and trastuzumab (OR 4.28, 95% CI (1.68, 10.91)); and pertuzumab, trastuzumab, and taxol (OR 4.56, 95% CI (1.8, 11.54)).”                      I do not understand, there is a significant association between pertuzumab, and its combination and what else?</p> <p><b>Page 8:</b> „The pre-and-post comorbidity comparison (Figure 3) suggested that there was a significant difference in ejection fractions for hypertension, dyslipidemia, diabetes mellitus, and cardiovascular disease.”                      From the figure I did not understand what the values listed below the graph represent and I did not see any statistical analysis and interpretation, plus there is a spelling mistake in the title above the figure</p> <p>In general, the statistical analysis is incomplete because the study design is poor and does not include important aspects of cardiotoxicity.                      The study must be rebuilt from the design stage with the clear definition, and in accordance with the international definitions of cardiotoxicity, of the cutoff values of the LVEF decline.                      The database needs to be improved and the moment of decline of LVEF should be highlighted according to the number of cycles of chemotherapy</p>	
<b>Minor</b> REVISION comments		
<b>Optional/General</b> comments		

**PART 2:**

	<b>Reviewer's comment</b>	<b>Author's comment</b> (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Are there ethical issues in this manuscript?</b>	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

**Review Form 1.6**

**Reviewer Details:**

Name:	<b>Stoicescu Laurentiu</b>
Department, University & Country	<b>Iuliu Hațieganu University of Medicine and Pharmacy, Romania</b>